Scholarlink

Background <p>Migraine is a common neurological disorder associated with various comorbidities, however its impact on mortality remains controversial. This study aimed to systematically evaluate the associations between migraine and the risk of all-cause, cardiovascular disease (CVD), and suicide mortality.</p> Methods <p>A comprehensive literature search of PubMed, Embase, and the Cochrane Library was conducted up to July 1, 2025, to identify eligible cohort studies assessing mortality outcomes in individuals with migraine. Random- or fixed-effects models were used to calculate pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup and meta-regression analyses were performed to explore the sources of heterogeneity. Study quality was assessed using the Newcastle-Ottawa Scale.</p> Results <p>Eighteen cohort studies, including 7,928,722 participants and 49,105 all-cause deaths, were included. No significant association was found between any migraine (AM) and all-cause mortality (HR = 0.93, 95% CI: 0.80–1.09, <i>I²</i> = 94.7%), CVD mortality (HR = 0.97, 95% CI: 0.80–1.18, <i>I²</i> = 80.6%), or suicide mortality (HR = 1.11, 95% CI: 0.98–1.26, <i>I²</i> = 15.5%). Considerable heterogeneity was observed across the studies for all-cause and CVD mortality. Subgroup analyses revealed a reduced risk of all-cause mortality in studies based on physician-diagnosed migraines and in those with a follow-up duration of less than 12 years. Meta-regression analyses identified the migraine diagnosis method and mean follow-up duration as potential sources of heterogeneity for all-cause mortality. However, the sex-stratified subgroup analysis demonstrated a higher CVD mortality risk with low heterogeneity in women with migraine (HR = 1.21, 95% CI: 1.08–1.34, <i>I²</i> = 0.0%), particularly in those with migraine with aura (MA) (HR = 1.28, 95% CI: 1.03–1.60, <i>I²</i> = 23.8%). Meta-regression analyses did not identify the sources of heterogeneity in the CVD mortality studies.</p> Conclusion <p>This systematic review and meta-analysis found no evidence linking AM with all-cause or cause-specific mortality. However, significant heterogeneity across studies and indications of an elevated CVD mortality risk in women with AM, particularly MA, render these findings inconclusive. Further research is required to elucidate this relationship and its underlying mechanisms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Migraine and risk of all-cause mortality and specific cause mortality: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Zongqing He,
  • Qichao Zhang,
  • Yi Sun,
  • Jing Yang,
  • Min Zhao

摘要

Background

Migraine is a common neurological disorder associated with various comorbidities, however its impact on mortality remains controversial. This study aimed to systematically evaluate the associations between migraine and the risk of all-cause, cardiovascular disease (CVD), and suicide mortality.

Methods

A comprehensive literature search of PubMed, Embase, and the Cochrane Library was conducted up to July 1, 2025, to identify eligible cohort studies assessing mortality outcomes in individuals with migraine. Random- or fixed-effects models were used to calculate pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Subgroup and meta-regression analyses were performed to explore the sources of heterogeneity. Study quality was assessed using the Newcastle-Ottawa Scale.

Results

Eighteen cohort studies, including 7,928,722 participants and 49,105 all-cause deaths, were included. No significant association was found between any migraine (AM) and all-cause mortality (HR = 0.93, 95% CI: 0.80–1.09, I² = 94.7%), CVD mortality (HR = 0.97, 95% CI: 0.80–1.18, I² = 80.6%), or suicide mortality (HR = 1.11, 95% CI: 0.98–1.26, I² = 15.5%). Considerable heterogeneity was observed across the studies for all-cause and CVD mortality. Subgroup analyses revealed a reduced risk of all-cause mortality in studies based on physician-diagnosed migraines and in those with a follow-up duration of less than 12 years. Meta-regression analyses identified the migraine diagnosis method and mean follow-up duration as potential sources of heterogeneity for all-cause mortality. However, the sex-stratified subgroup analysis demonstrated a higher CVD mortality risk with low heterogeneity in women with migraine (HR = 1.21, 95% CI: 1.08–1.34, I² = 0.0%), particularly in those with migraine with aura (MA) (HR = 1.28, 95% CI: 1.03–1.60, I² = 23.8%). Meta-regression analyses did not identify the sources of heterogeneity in the CVD mortality studies.

Conclusion

This systematic review and meta-analysis found no evidence linking AM with all-cause or cause-specific mortality. However, significant heterogeneity across studies and indications of an elevated CVD mortality risk in women with AM, particularly MA, render these findings inconclusive. Further research is required to elucidate this relationship and its underlying mechanisms.